NCT06580314 2026-03-24Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerNRG OncologyPhase 3 Recruiting880 enrolled
NCT02446600 2026-03-05Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting579 enrolled 17 charts